Search

Author/Creator Siebers, Nicholas

1. 290 Development and first-in-human characterization of an ICOSL and BAFF bispecific inhibitor AMG 570 for SLE treatment. (April 2019)

Authors:
Cheng, Laurence E; Hsu, Hailing; Kankam, Martin; Siebers, Nicholas; Stoltz, Randall; Abuqayyas, Lubna; Ertik, Bella; Sullivan, Barbara; Zhou, Lei; Parnes, Jane R
Journal:
Lupus science & medicine
Issue:
Volume 6(2019)supplement 1
Page Start:
A210
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Absorption, metabolism and excretion of pictilisib, a potent pan-class I phosphatidylinositol-3-Kinase (PI3K) inhibitor, in rats, dogs, and humans. (3rd July 2021)

Authors:
Yue, Qin; Khojasteh, S. Cyrus; Cho, Sungjoon; Ma, Shuguang; Mulder, Teresa; Chen, John; Pang, Jodie; Ding, Xiao; Deese, Alan; Pellet, Jackson D.; Siebers, Nicholas; Joas, Lori; Salphati, Laurent; Ware, Joseph A.
Journal:
Xenobiotica
Issue:
Volume 51:Number 7(2021)
Page Start:
796
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Investigation of the absolute bioavailability and human mass balance of navoximod, a novel IDO1 inhibitor. Issue 8 (14th June 2019)

Authors:
Ma, Shuguang; Suchomel, Julia; Yanez, Evelyn; Yost, Edward; Liang, Xiaorong; Zhu, Rui; Le, Hoa; Siebers, Nicholas; Joas, Lori; Morley, Roland; Royer‐Joo, Stephanie; Pirzkall, Andrea; Salphati, Laurent; Ware, Joseph A.; Morrissey, Kari M.
Journal:
British journal of clinical pharmacology
Issue:
Volume 85:Issue 8(2019)
Page Start:
1751
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗